Fourth, in advanced stages of disease, the masking effect between podoplanin and CLEC-2 has been proposed as a potential source of underestimation of free soluble CLEC-2 levels in plasma, particularly in patients with higher tumor burden or increased podoplanin expression. This evidence concerns the gene PDPN and neoplasm.